Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain

Por Abram, Michael E., Parniak, Michael A.
Publicado em 2005

The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site

Por Abram, Michael E, Sarafianos, Stefan G, Parniak, Michael A
Publicado em 2010

A Cell-Based Strategy To Assess Intrinsic Inhibition Efficiencies of HIV-1 Reverse Transcriptase Inhibitors

Por Abram, Michael E., Tsiang, Manuel, White, Kirsten L., Callebaut, Christian, Miller, Michael D.
Publicado no Antimicrob Agents Chemother (2015)

Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication

Por Abram, Michael E., Ferris, Andrea L., Shao, Wei, Alvord, W. Gregory, Hughes, Stephen H.
Publicado em 2010

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

Por Abram, Michael E., Ram, Renee R., Margot, Nicolas A., Barnes, Tiffany L., White, Kirsten L., Callebaut, Christian, Miller, Michael D.
Publicado no PLoS One (2017)

Mutations in HIV-1 Reverse Transcriptase Affect the Errors Made in a Single Cycle of Viral Replication

Por Abram, Michael E., Ferris, Andrea L., Das, Kalyan, Quinoñes, Octavio, Shao, Wei, Tuske, Steven, Alvord, W. Gregory, Arnold, Eddy, Hughes, Stephen H.
Publicado em 2014

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From...

Por Post, Frank A., Tebas, Pablo, Clarke, Amanda, Cotte, Laurent, Short, William R., Abram, Michael E., Jiang, Shuping, Cheng, Andrew, Das, Moupali, Fordyce, Marshall W.
Publicado no J Acquir Immune Defic Syndr (2017)

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

Por Raffi, François, Orkin, Chloe, Clarke, Amanda, Slama, Laurence, Gallant, Joel, Daar, Eric, Henry, Keith, Santana-Bagur, Jorge, Stein, David K., Bellos, Nicholaos, Scarsella, Anthony, Yan, Mingjin, Abram, Michael E., Cheng, Andrew, Rhee, Martin S.
Publicado no J Acquir Immune Defic Syndr (2017)

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Por Abram, Michael E., Hluhanich, Rebecca M., Goodman, Derrick D., Andreatta, Kristen N., Margot, Nicolas A., Ye, Linda, Niedziela-Majka, Anita, Barnes, Tiffany L., Novikov, Nikolai, Chen, Xiaowu, Svarovskaia, Evguenia S., McColl, Damian J., White, Kirsten L., Miller, Michael D.
Publicado em 2013

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm...

Por Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Publicado no J Acquir Immune Defic Syndr (2016)